Treating Central and Treatment-Emergent Sleep Apnea

Opening Clinical Case

Three patients all have a similar central apnea index, but they should not receive identical treatment. One has opioid-associated CSA, one has heart-failure-associated CSA, and one has transient treatment-emergent CSA after starting PAP. The right treatment starts with the cause, symptoms, comorbidities, and physiologic pattern—not with the device catalog.aasm+1

That is the central message of this chapter. In CSA, the index is a clue, not the treatment plan. If you do not ask why the breathing is unstable, you are likely to treat the number while missing the disease.

What You Should Be Able to Do After This Chapter

By the end of this chapter, you should be able to:

• Start with the cause of CSA rather than the mode.

• Recognize when CPAP has a role and when persistent central events require escalation.

• Understand why bilevel without a backup rate is discouraged in CSA.

• Explain the physiologic role of ASV, oxygen, acetazolamide, and phrenic nerve stimulation.

• Approach treatment-emergent CSA without overreacting to early events.

• Match therapy to symptoms, etiology, and cardiac context.

The Core Concept

The treatment of CSA begins by treating the cause when possible. If the patient has a reversible driver, address it. If the patient is on respiratory depressants, review them. If heart failure is present, coordinate heart-failure management. If altitude, renal disease, or neurologic disease contributes, address that context too.aasm+1

Medical explanation: central apnea is usually a manifestation of instability in ventilatory control, drive, or gas exchange. Explain It Like I’m 10: if the fire alarm keeps sounding because the kitchen is on fire, replacing the alarm does not solve the kitchen fire. Back to clinical medicine: device therapy can help, but it should not replace etiologic thinking.

A practical treatment flow helps keep the logic straight.

Treat the Cause When Possible

Optimization of the underlying disorder should be the first move whenever feasible. That includes heart-failure management, medication review, and addressing altitude, renal, or neurologic contributors. In opioid-associated CSA, review the medication list carefully and coordinate with the prescribing clinician rather than issuing abrupt and unsafe medication instructions. In heart-failure-associated CSA, the cardiopulmonary context matters as much as the sleep study.aasm+1

The fire-alarm analogy is useful because it reminds us that the signal is often downstream of the cause. If the kitchen is still on fire, the alarm will keep sounding. Likewise, if the physiologic driver persists, the CSA will often persist too. The sleep clinician should be part of the solution, but not by pretending the cause does not matter.

CPAP

CPAP can have a role in selected CSA settings, especially when there is coexisting obstruction or when breathing stabilization is useful. The key is to verify response rather than assuming success. In some patients, CPAP reduces instability enough to help; in others, persistent central events require reconsideration.aasm+1

CPAP is not a universal answer for CSA, but it is not useless either. The question is whether the patient’s physiology responds. If central events persist despite reasonable CPAP use, that is a signal to reassess etiology, leak, pressure, and whether another therapy is more appropriate. A good CPAP download is not the end of the story if the patient is still symptomatic or the central events remain prominent.

Bilevel PAP With a Backup Rate

Bilevel with a backup rate can provide EPAP for obstruction, pressure support for ventilation, and timed breaths when spontaneous breaths do not occur. That makes it a rational choice in selected CSA etiologies where ventilation support is needed. The backup rate is the key distinguishing feature. Without it, bilevel may not solve the problem.aasm+1

Monitoring matters because the purpose is not merely to raise the numbers on a device display. The purpose is to stabilize breathing and improve outcomes. If the patient needs ventilatory assistance, bilevel with backup rate can be appropriate. If the patient does not, then the extra complexity may add little and can add confusion.

Why Bilevel Without a Backup Rate May Be Problematic

Spontaneous bilevel can increase ventilation enough to lower carbon dioxide. In a patient with unstable ventilatory control, that can drop CO₂ below the apneic threshold and worsen central instability. That is why bilevel without a backup rate is not a universal CSA treatment. In several CSA etiologies, the 2025 AASM guideline suggests against bilevel PAP without a backup rate.guidelinecentral+2

Explain It Like I’m 10: giving larger breaths without controlling timing may make an unstable breathing thermostat even more unstable in some patients. Back to clinical medicine: if the problem is ventilatory instability, spontaneous bilevel may make the instability worse rather than better.

Adaptive Servo-Ventilation

ASV provides breath-by-breath support to treat ventilatory instability. It is one of the more targeted tools for central apnea patterns, especially when instability is the dominant problem. The 2025 AASM guideline conditionally supports ASV in selected CSA settings, but it also emphasizes cardiac evaluation and experienced-center monitoring in higher-risk cardiac patients. Shared decision-making matters because the evidence is nuanced and patient context matters.aasm+1

Cardiac context is the major caution point. Older blanket avoidance statements no longer capture the whole modern picture, but heart failure with reduced ejection fraction still requires careful evaluation and monitoring. In higher-risk patients, the right setting is not casual prescribing. It is deliberate selection with follow-up and expertise.aasm+1

Oxygen

Low-flow oxygen can help selected CSA etiologies, especially in heart-failure-related or high-altitude-related breathing instability. Its value is partly in reducing hypoxic ventilatory instability. But oxygen is not the same as ventilatory support. It can improve oxygenation without fully correcting the underlying control problem.aasm+1

That distinction matters. Oxygen may be useful in some patients, but it is not a universal CSA treatment. It should be chosen for the right physiology and monitored for the actual response. If the central pattern persists or symptoms remain, oxygen alone may not be enough.

Acetazolamide

Acetazolamide alters ventilatory control by promoting a mild metabolic acidosis that can reduce loop gain and stabilize breathing. It has a role in selected CSA and altitude-related settings. That makes it a physiology-based option rather than a one-size-fits-all therapy. It is helpful precisely because it changes the control system, not just the airway.aasm+1

The limitations are familiar: renal considerations, electrolyte issues, contraindications, and adverse effects all matter. The medication should be individualized. A patient with renal disease or electrolyte vulnerability needs more caution. The sleep clinician should know enough pharmacology to avoid turning a ventilatory tool into a metabolic problem.

Transvenous Phrenic Nerve Stimulation

Transvenous phrenic nerve stimulation directly helps activate the diaphragm during sleep. It is an implantable treatment for selected patients and is not first-line for every central event. The 2025 AASM guideline includes it as a conditional option in specific CSA settings, including primary CSA and CSA due to heart failure. It requires implantation, follow-up, and patient selection.aasm+2

The important practical point is that invasive does not mean automatic, and novel does not mean universal. This is a specialized therapy for selected patients who fit the indication and have not done well with, or are not suited for, other approaches. It is another example of why the device catalog should not lead the conversation.

Treatment-Emergent CSA Management

Treatment-emergent CSA should be approached methodically, not emotionally. First confirm that the central events are real. Then assess symptoms and severity, check leak and pressure, review medications and comorbidities, and decide whether observation is reasonable. Some cases are transient and improve with time or stabilization of PAP therapy.aasm+1

The mistake is to overreact to a few early events by changing to a much more complex mode before the pattern is clear. That can solve nothing and create new problems. Instead, use objective data and follow-up to decide whether the central events are diminishing, persisting, or becoming clinically significant. If they persist and matter, then escalation becomes appropriate.

Diagnostic Reasoning

The main diagnostic move is to link the central events to the likely etiology. If the patient has opioid exposure, think medication-related CSA. If the patient has heart failure, think heart-failure-associated CSA or Cheyne–Stokes pattern. If the patient recently started PAP, think treatment-emergent CSA. If the patient is at altitude, think high-altitude periodic breathing. If there is renal or neurologic disease, those must also be considered.aasm+1

That means the treatment choice is really a diagnosis-specific decision. CPAP, bilevel with backup rate, ASV, oxygen, acetazolamide, and TPNS are all tools, but none of them should be chosen by habit. The phenotype and the cause determine the answer.

Understanding the Relevant Data

The data that matter most are not just the CAI. You need symptoms, comorbidities, oxygenation, cardiac function when relevant, medication exposure, altitude history, and the PSG pattern. You also need to know whether obstruction coexists, because some central apnea patients still benefit from airway splinting as part of the plan. The report should be read as a pattern, not just a score.aasm+1

A second key point is that response should be verified objectively. If symptoms remain, if the index remains high, or if the clinical picture does not match the download, the treatment should be revisited. In CSA, you are often managing a breathing control disorder rather than a single-number disorder. That is why follow-up data matter so much.

Return to the Opening Case

The opioid-associated CSA patient needs medication review and a physiologically appropriate therapy choice, not automatic ASV. The heart-failure-associated CSA patient needs etiologic attention and a cardiac-aware therapy discussion. The patient with transient treatment-emergent CSA may need observation, leak review, and objective reassessment before any escalation. The similar indices do not mean similar disease.aasm+1

That is the point. CSA treatment begins with etiology, symptoms, and physiology. The device comes after the diagnosis, not before it.

What the Attending Will Ask

1. What should be treated first in CSA? The underlying cause when possible.aasm+1

1. When can CPAP help CSA? In selected patients, especially when there is coexisting obstruction or breathing stabilization benefit.aasm+1

1. Why is bilevel without backup rate discouraged? Because it may increase ventilation, lower CO₂, and worsen instability.guidelinecentral+1

1. When is bilevel with a backup rate used? When ventilation support and timed breaths are needed in selected CSA etiologies.aasm+1

1. What is ASV for? Breath-by-breath stabilization of ventilatory instability.aasm+1

1. Why is heart failure context important for ASV? Because cardiac function and risk profile affect appropriateness and monitoring.aasm+1

1. When can oxygen help? In selected CSA etiologies such as heart failure or altitude-related periodic breathing.aasm+1

1. What is the role of TPNS? A selected implantable option for certain CSA patients, not first-line for everyone.aasm+1

Mistakes Smart Fellows Still Make

1. Immediately prescribing ASV for every central event. This happens because ASV feels definitive. It matters because not every CSA patient needs it. Avoid it by identifying the cause first.

1. Using spontaneous bilevel automatically. This happens because bilevel sounds like more support. It matters because it may worsen instability without a backup rate. Avoid it by matching mode to physiology.

1. Ignoring ejection fraction or cardiac context. This happens because sleep and cardiology can feel like separate worlds. It matters because cardiac function changes therapy selection and monitoring. Avoid it by checking the heart when relevant.

1. Failing to reassess transient treatment-emergent events. This happens because early central events can look alarming. It matters because some cases are temporary. Avoid it by reviewing follow-up data before escalating.

1. Treating the index while ignoring symptoms and etiology. This happens because the number is easy to chase. It matters because the patient’s actual problem may be elsewhere. Avoid it by making etiology and symptoms part of the treatment decision.

The Board Exam Is Trying to Trick You

1. The stem gives opioid-associated CSA. The trap is to jump straight to ASV. The correct answer is to review the medication/substance issue and choose therapy based on the overall picture.pubmed.ncbi.nlm.nih+2

1. The stem gives heart-failure-associated CSA. The trap is to use the same treatment as for other etiologies. The correct answer is to consider heart-failure context and choose therapy accordingly.aasm+1

1. The stem gives bilevel without backup rate. The trap is to assume it is always fine. The correct answer is that spontaneous bilevel can be problematic in several CSA settings.guidelinecentral+1

1. The stem gives treatment-emergent central events on early PAP. The trap is to overreact. The correct answer is to confirm, reassess, and decide whether observation is reasonable.aasm+1

1. The stem asks what matters most in CSA treatment selection. The trap is to answer CAI alone. The correct answer is etiology, symptoms, comorbidity, and physiology.

How to Explain This to a Patient

“Central sleep apnea is different from obstructive sleep apnea. The problem is not just a blocked airway; it is that the breathing signal becomes unstable. We try to identify why that is happening—such as heart failure, certain medications, altitude, or a change after PAP starts—and then choose the treatment that fits that cause. Sometimes the best first step is treating the underlying problem; sometimes we add a breathing device or another therapy.”

Practical Pearls

• CSA treatment starts with cause, symptoms, and physiology.

• Treat the underlying condition whenever possible.

• CPAP may help selected CSA patients, especially with coexisting obstruction.aasm+1

• Bilevel without a backup rate can be problematic in CSA.guidelinecentral+1

• ASV is a targeted therapy for ventilatory instability and requires cardiac-aware selection.aasm+1

• Oxygen and acetazolamide have selected roles, not universal ones.aasm+1

• TPNS is a selected implantable option, not first-line for everyone.aasm+1

• Treatment-emergent CSA can be transient and should be reassessed.

• Symptoms and etiology matter as much as the index.

• Objective follow-up is essential.

The Bottom Line

• CSA treatment begins with etiology, symptoms, comorbidities, and physiology—not with the device catalog.

• Treat the cause when possible.

• CPAP may help selected CSA cases, but persistent central events require reconsideration.aasm+1

• Bilevel with a backup rate is different from spontaneous bilevel, and the latter may be problematic.guidelinecentral+1

• ASV is a targeted tool for ventilatory instability, with cardiac-aware monitoring in higher-risk patients.aasm+1

• Oxygen and acetazolamide have selected roles.aasm+1

• TPNS is an invasive, selected therapy, not first-line for every central event.aasm+1

• Treatment-emergent CSA often needs reassessment rather than immediate escalation.

• Follow-up should confirm that the chosen therapy actually helps.

• The CAI is not a treatment plan.

Question 1

What is the best first step in treating CSA?

A. Browse the device catalog B. Identify and address the underlying cause when possible C. Switch immediately to ASV D. Ignore symptoms and focus on the index E. Use spontaneous bilevel for everyone

Question 2

Why can bilevel without a backup rate be problematic in CSA?

A. It always lowers oxygen too much B. It may increase ventilation, lower CO₂, and worsen instability C. It is identical to CPAP D. It is only for snoring E. It cannot be used with any mask

Question 3

What is the role of CPAP in CSA?

A. No role ever B. It may help selected patients, especially with coexisting obstruction or stabilization benefit C. It is the same as ASV D. It always cures CSA E. It is only for altitude CSA

Question 4

Which therapy directly targets ventilatory instability breath by breath?

A. Oxygen B. ASV C. Oral appliance D. Positional therapy E. Nasal saline

Question 5

What is the correct approach to treatment-emergent CSA early after PAP starts?

A. Always switch immediately to invasive therapy B. Confirm the events, check leak and pressure, review comorbidities, and reassess objectively C. Ignore it and never follow up D. Call it permanent CSA immediately E. Stop PAP forever

Question 1

Correct answer: B. Identify and address the underlying cause when possible.

Why it is correct: the 2025 AASM guideline emphasizes individualized, etiology-driven treatment.aasm+1 Why the others are wrong: A, C, D, and E skip the diagnostic step or overgeneralize treatment. Learning point: cause first, mode second.

Question 2

Correct answer: B. It may increase ventilation, lower CO₂, and worsen instability.

Why it is correct: spontaneous bilevel can worsen ventilatory instability in some CSA settings.guidelinecentral+1 Why the others are wrong: A, C, D, and E are false. Learning point: more pressure is not always better.

Question 3

Correct answer: B. It may help selected patients, especially with coexisting obstruction or stabilization benefit.

Why it is correct: CPAP has a selected role in CSA and should be judged by response.aasm+1 Why the others are wrong: A, C, D, and E are incorrect. Learning point: CPAP can be useful, but it is not universal.

Question 4

Correct answer: B. ASV.

Why it is correct: ASV adjusts support breath by breath to stabilize ventilatory instability.aasm+1 Why the others are wrong: oxygen improves oxygenation, not breath-by-breath instability; the others do not address CSA physiology in this way. Learning point: ASV is a control-system therapy.

Question 5

Correct answer: B. Confirm the events, check leak and pressure, review comorbidities, and reassess objectively.

Why it is correct: treatment-emergent CSA may be transient and should be reassessed before major changes.aasm+1 Why the others are wrong: A, C, D, and E are overreactions or omissions. Learning point: early central events require follow-up, not panic.